Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

abbvie inc. - ABBV

ABBV

Close Chg Chg %
228.77 -4.43 -1.94%

Closed Market

224.34

-4.43 (1.94%)

Volume: 5.41M

Last Updated:

Feb 19, 2026, 3:59 PM EDT

Trade Now

Company Overview: abbvie inc. - ABBV

ABBV Key Data

Open

$228.40

 Day Range

223.02 - 229.37

52 Week Range

164.39 - 244.81

 Market Cap

$409.15B

Shares Outstanding

1.77B

 Public Float

1.77B

Beta

0.34

 Rev. Per Employee

N/A

P/E Ratio

95.96

 EPS

$1.35

Yield

290.75%

 Dividend

$1.73

EX-DIVIDEND DATE

Jan 16, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

7.47M

  

ABBV Performance

1 Week
 
 -1.20%
 
1 Month
 
 6.70%
 
3 Months
 
 -3.20%
 
1 Year
 
 13.18%
 
5 Years
 
 117.81%
 

ABBV Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 31
Full Ratings ➔

About abbvie inc. - ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

ABBV At a Glance

AbbVie, Inc.
1 North Waukegan Road
North Chicago, Illinois 60064-6400
Phone 1-847-932-7900 Revenue 61.16B
Industry Pharmaceuticals: Major Net Income 4.23B
Sector Health Technology 2025 Sales Growth 8.567%
Fiscal Year-end 12 / 2026 Employees N/A
View SEC Filings

ABBV Valuation

P/E Current 95.96
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 95.863
Price to Sales Ratio 6.624
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA N/A
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

ABBV Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover N/A
Total Asset Turnover N/A

ABBV Liquidity

Current Ratio N/A
Quick Ratio N/A
Cash Ratio N/A

ABBV Profitability

Gross Margin 83.707
Operating Margin 34.686
Pretax Margin 10.786
Net Margin 6.91
Return on Assets N/A
Return on Equity N/A
Return on Total Capital N/A
Return on Invested Capital N/A

ABBV Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Abbvie Inc. - ABBV

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
58.05B 54.32B 56.33B 61.16B
Sales Growth
+3.30% -6.44% +3.71% +8.57%
Cost of Goods Sold (COGS) incl D&A
16.45B 16.65B 16.83B 9.96B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- 8.47B 8.70B 8.39B
Depreciation
- 778.00M 752.00M 764.00M
Amortization of Intangibles
7.69B 7.95B 7.62B 7.38B
COGS Growth
-4.08% +1.25% +1.09% -40.79%
Gross Income
41.61B 37.67B 39.50B 51.20B
Gross Income Growth
+6.54% -9.47% +4.87% +29.60%
Gross Profit Margin
+71.67% +69.35% +70.12% +83.71%
2022 2023 2024 2025 5-year trend
SG&A Expense
19.01B 19.59B 22.88B 22.84B
Research & Development
6.49B 7.04B 8.31B 9.01B
Other SG&A
12.52B 12.55B 14.56B 13.84B
SGA Growth
-1.54% +3.05% +16.81% -0.14%
Other Operating Expense
- - - 7.14B
-
Unusual Expense
7.26B 10.53B 11.19B 12.63B
EBIT after Unusual Expense
15.34B 7.55B 5.44B 8.58B
Non Operating Income/Expense
485.00M 1.06B 1.23B 644.00M
Non-Operating Interest Income
- 186.00M 540.00M 648.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
2.35B 2.36B 2.95B 2.63B
Interest Expense Growth
-4.21% +0.60% +25.17% -11.07%
Gross Interest Expense
2.35B 2.36B 2.95B 2.63B
Interest Capitalized
- - - -
-
Pretax Income
13.48B 6.25B 3.72B 6.60B
Pretax Income Growth
+3.76% -53.62% -40.54% +77.53%
Pretax Margin
+23.21% +11.51% +6.60% +10.79%
Income Tax
1.63B 1.38B (570.00M) 2.36B
Income Tax - Current - Domestic
- 2.65B 3.27B (331.00M)
Income Tax - Current - Foreign
- 916.00M 994.00M 1.21B
Income Tax - Deferred - Domestic
- (1.51B) (2.32B) (1.30B)
Income Tax - Deferred - Foreign
- (419.00M) (565.00M) (146.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- (54.00M) (43.00M) (40.00M)
Consolidated Net Income
11.79B 4.83B 4.25B 4.23B
Minority Interest Expense
9.00M 10.00M 8.00M 7.00M
Net Income
11.78B 4.82B 4.24B 4.23B
Net Income Growth
+2.74% -59.09% -12.07% -0.28%
Net Margin Growth
+20.29% +8.87% +7.52% +6.91%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
11.78B 4.82B 4.24B 4.23B
Preferred Dividends
- - - -
-
Net Income Available to Common
11.78B 4.82B 4.24B 4.23B
EPS (Basic)
- 6.6527 2.7262 2.3957
EPS (Basic) Growth
- +2.68% -59.02% -12.12%
Basic Shares Outstanding
- 1.77B 1.77B 1.77B
EPS (Diluted)
6.6266 2.7186 2.3903 2.3835
EPS (Diluted) Growth
+2.68% -58.97% -12.08% -0.28%
Diluted Shares Outstanding
1.78B 1.77B 1.77B 1.77B
EBITDA
- 31.07B 26.78B 25.01B
EBITDA Growth
- +9.90% -13.80% -6.61%
EBITDA Margin
- +53.52% +49.30% +44.40%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 252.92
Number of Ratings 31 Current Quarters Estimate 2.997
FY Report Date 03 / 2026 Current Year's Estimate 14.528
Last Quarter’s Earnings 2.71 Median PE on CY Estimate N/A
Year Ago Earnings 10.00 Next Fiscal Year Estimate 16.111
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 18 17 25 24
Mean Estimate 3.00 3.76 14.53 16.11
High Estimates 3.17 3.99 15.25 17.43
Low Estimate 2.83 3.58 14.10 14.95
Coefficient of Variance 2.04 3.00 1.33 3.47

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 18 18 18
OVERWEIGHT 2 2 3
HOLD 10 11 8
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Abbvie Inc. - ABBV

Date Name Shares Transaction Value
Jan 7, 2026 Robert J. Alpern Director 10,257 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 7, 2026 Edward J. Rapp Director 28,498 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 7, 2026 Susan E. Quaggin Director 707 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Kevin K. Buckbee SVP, CONTROLLER 2,794 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 3, 2025 Kevin K. Buckbee SVP, CONTROLLER 2,373 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 3, 2025 Kevin K. Buckbee SVP, CONTROLLER 11,496 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $203.41 per share 2,338,401.36
Mar 3, 2025 Kevin K. Buckbee SVP, CONTROLLER 28,906 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $105.92 per share 3,061,723.52
Mar 3, 2025 Kevin K. Buckbee SVP, CONTROLLER 22,384 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $93.5 per share 2,092,904.00
Mar 3, 2025 Kevin K. Buckbee SVP, CONTROLLER 12,646 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $203.4 per share 2,572,196.40
Mar 3, 2025 Timothy J. Richmond EVP, CHIEF HR OFFICER N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 3, 2025 Timothy J. Richmond EVP, CHIEF HR OFFICER 44,284 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $203.63 per share 9,017,550.92
Mar 3, 2025 Timothy J. Richmond EVP, CHIEF HR OFFICER 49,113 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $202.92 per share 9,966,009.96
Mar 3, 2025 Timothy J. Richmond EVP, CHIEF HR OFFICER 62,186 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $201.97 per share 12,559,706.42
Mar 3, 2025 Timothy J. Richmond EVP, CHIEF HR OFFICER 66,494 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $114.36 per share 7,604,253.84
Mar 3, 2025 Timothy J. Richmond EVP, CHIEF HR OFFICER 44,284 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $203.64 per share 9,017,993.76
Mar 3, 2025 Timothy J. Richmond EVP, CHIEF HR OFFICER 45,810 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $202.93 per share 9,296,223.30
Mar 3, 2025 Timothy J. Richmond EVP, CHIEF HR OFFICER 50,591 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $202.06 per share 10,222,417.46

Abbvie Inc. in the News